<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease - Walters, JAE - 2017 | Cochrane Library</title> <meta content="Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease - Walters, JAE - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001390.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease - Walters, JAE - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001390.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001390.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Julia AE Walters" name="citation_author"/> <meta content="La Trobe University" name="citation_author_institution"/> <meta content="Julia.Walters@utas.edu.au" name="citation_author_email"/> <meta content="Joanne Ngie Qing Tang" name="citation_author"/> <meta content="University of Tasmania" name="citation_author_institution"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Richard Wood‐Baker" name="citation_author"/> <meta content="University of Tasmania" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD001390.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001390.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001390.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001390.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cause of Death; Community-Acquired Infections [prevention &amp; control]; Pneumococcal Infections [mortality, *prevention &amp; control]; Pneumococcal Vaccines [*administration &amp; dosage]; Pneumonia, Pneumococcal [prevention &amp; control]; Pulmonary Disease, Chronic Obstructive [*complications, mortality]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001390.pub4&amp;doi=10.1002/14651858.CD001390.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001390\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001390\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001390.pub4",title:"Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease",firstPublishedDate:"Jan 24, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001390.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001390.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001390.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001390.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001390.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001390.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001390.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001390.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001390.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001390.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8834 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001390.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/appendices#CD001390-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/table_n/CD001390StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/table_n/CD001390StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information#CD001390-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Julia AE Walters</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information#CD001390-cr-0003">Joanne Ngie Qing Tang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information#CD001390-cr-0004">Phillippa Poole</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information#CD001390-cr-0005">Richard Wood‐Baker</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information/en#CD001390-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001390.pub4">https://doi.org/10.1002/14651858.CD001390.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001390-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001390-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001390-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001390-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001390-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001390-abs-0001" lang="en"> <section id="CD001390-sec-0001"> <h3 class="title" id="CD001390-sec-0001">Background</h3> <p>People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs. </p> </section> <section id="CD001390-sec-0002"> <h3 class="title" id="CD001390-sec-0002">Objectives</h3> <p>To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD. </p> </section> <section id="CD001390-sec-0003"> <h3 class="title" id="CD001390-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016. </p> </section> <section id="CD001390-sec-0004"> <h3 class="title" id="CD001390-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD. </p> </section> <section id="CD001390-sec-0005"> <h3 class="title" id="CD001390-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type. </p> </section> <section id="CD001390-sec-0006"> <h3 class="title" id="CD001390-sec-0006">Main results</h3> <p>For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV<sub>1</sub>) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate. </p> <p>Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23. </p> </section> <section id="CD001390-sec-0007"> <h3 class="title" id="CD001390-sec-0007">Authors' conclusions</h3> <p>Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001390-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001390-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001390-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001390-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001390-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001390-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001390-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001390-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001390-abs-0004" lang="en"> <h3>Do injectable pneumococcal vaccines prevent pneumonia in people with COPD?</h3> <p>We wanted to find out if pneumococcal vaccination for people with chronic obstructive pulmonary disease (COPD) reduces the risk of pneumonia and associated mortality. We found a total of 12 studies including 2171 participants. Evidence gathered in this review is current to December 2015. </p> <p><b>Background</b> </p> <p>People with COPD are at increased risk of respiratory illness such as pneumonia due to a bacterium called <i>Streptococcus pneumonia</i>e, other community‐acquired pneumonias and acute COPD exacerbations. These illnesses increase mortality and are associated with increased healthcare costs. </p> <p><b>Study characteristics</b> </p> <p>For this updated review, we identified five new studies (606 participants), bringing the total number of studies to 12, involving 2171 participants with COPD. The average age of participants was 66 years, 67% were male and participants had received a diagnosis of moderate to severe COPD. Eleven studies compared an injectable vaccine versus a control, and one study compared two different types of injectable vaccine. </p> <p><b>Key results</b> </p> <p>People who were vaccinated were less likely to experience an episode of community‐acquired pneumonia; 19 people with COPD (95% confidence interval (CI) 13 to 52) would have to be vaccinated to prevent one episode of pneumonia. Vaccination made no difference in the risk of pneumococcal pneumonia due to <i>S pneumonia</i>e or in the chance of dying or of being admitted to hospital. People who were vaccinated were less likely to experience a COPD exacerbation; eight people with COPD (95% CI 5 to 58) would have to be vaccinated to prevent one person from having an acute exacerbation. We found no difference in effectiveness between the two types of injectable vaccine. </p> <p><b>Quality of the evidence</b> </p> <p>Evidence in this review is generally independent and reliable, and we are moderately certain about the results. </p> <p><b>Conclusions</b> </p> <p>In line with current guidance, this review suggests that all people with COPD should be given pneumococcal vaccination to provide some protection against community‐acquired pneumonia, and to reduce the chance of an acute exacerbation. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001390-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001390-sec-0089"></div> <h3 class="title" id="CD001390-sec-0090">Implications for practice</h3> <section id="CD001390-sec-0090"> <p>Moderate‐quality evidence derived from RCTs included in this review suggests that injectable polyvalent pneumococcal vaccines provide protection against community‐acquired pneumonia and reduce the likelihood of exacerbations of chronic obstructive pulmonary disease (COPD). Evidence was insufficient for comparisons of different pneumococcal vaccine types. Evidence in this review supports pneumococcal vaccination for people with COPD, as recommended by respiratory guidelines. </p> </section> <h3 class="title" id="CD001390-sec-0091">Implications for research</h3> <section id="CD001390-sec-0091"> <p>Pneumococcal immunisation among children and older adults in many countries has reduced the incidence and changed the epidemiology of pneumococcal disease. Future randomised controlled trials restricted to people with COPD will be difficult to conduct with adequate power to detect significant effects, especially for rare events such as confirmed pneumococcal pneumonia. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001390-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001390-sec-0022"></div> <div class="table" id="CD001390-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pneumoccocal vaccination to prevent pneumonia in chronic obstructive pulmonary disease?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease? </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> pneumococcal vaccine<br/> <b>Comparison:</b> control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pneumococcal vaccine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia, community acquired, at least 1 episode<br/> Follow‐up: range 6 to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (67 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.59 (0.41 to 0.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1372<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitations with lack of participant blinding and no use of placebo in 3 studies. NNTB to prevent 1 episode of CAP = 19 (95% CI 13 to 52) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumococcal pneumonia, at least 1 episode<br/> Follow‐up: range 6 to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.26<br/> (0.05 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1158<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very few confirmed episodes of pneumococcal pneumonia. Rate of pneumococcal CAP to total CAP from 2008 to 2013 varied from 17.1% to 37.3% of cases (<a href="./references#CD001390-bbs2-0147" title="RodrigoC , BewickT , SheppardC , GreenwoodS , McKeeverTM , TrotterCL , et al. Impact of infant 13‐valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. European Respiratory Journal2015;45(6):1632‐41. ">Rodrigo 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from cardiorespiratory causes<br/> Follow‐up: range 24 to 48 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (70 to 153) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.07<br/> (0.69 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>888<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from all causes<br/> Follow‐up: range 12 to 48 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1000<br/> (125 to 217) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.72 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1053<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission: any cause, at least 1 episode<br/> Follow‐up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (29 to 140) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/> (0.32 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD exacerbation: at least 1 episode<br/> Follow‐up: range 6 to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>482 per 1000<br/> (377 to591) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.60 (0.39 to 0.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitations with lack of or unclear participant blinding in 3 studies. NNTB = 8 (95% CI 5 to 58); see <a href="./full#CD001390-fig-0001">Figure 1</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function: FEV<sub>1</sub> (L)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean lung function: FEV<sub>1</sub> (L) was 1.43 L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean lung function: FEV<sub>1</sub> (L) in the intervention group was 0.12 L lower (7.17 lower to 6.93 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference in lung function seen at 3 or 24 months in 1 study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; OR: odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Study limitations increase risk of performance and detection bias. </p> <p><sup>b</sup>substantial heterogeneity present. </p> <p><sup>c</sup>Wide confidence interval; few events in 2 studies, no events in 1 study. </p> <p><sup>d</sup>Wide confidence interval; effect size includes the null. </p> <p><sup>e</sup>Single study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD001390-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="In the control group, 608 out of 1000 people had one or more exacerbations over 6 to 24 months, compared with 482 (95% CI 377 to 591) out of 1000 for the active treatment group." data-id="CD001390-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the control group, 608 out of 1000 people had one or more exacerbations over 6 to 24 months, compared with 482 (95% CI 377 to 591) out of 1000 for the active treatment group. </p> </div> </div> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001390-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001390-sec-0023"></div> <section id="CD001390-sec-0024"> <h3 class="title" id="CD001390-sec-0024">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is characterised by airflow obstruction that is not fully reversible. Data from 12 countries in the Burden of Lung Disease (BOLD) initiative show that more than 10% of adults have COPD at Stage II or higher, as defined by <a href="./references#CD001390-bbs2-0127" title="GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.com (accessed 2 July 2016). ">GOLD 2016</a>. Prevalence and staging vary across countries between men and women (<a href="./references#CD001390-bbs2-0115" title="BuistAS , McBurnieMA , VollmerWM , GillespieS , BurneyP , ManninoDM , et al. International variation in the prevalence of COPD (the BOLD study): a population‐based prevalence study. The Lancet2007;370(9589):741‐50. ">Buist 2007</a>) and increase with age. Worldwide, COPD was the fifth‐ leading cause of death in 2011, and it was the seventh‐leading cause of lost disability‐adjusted life years (DALYs) (<a href="./references#CD001390-bbs2-0158" title="World Health Organization. Global health estimates ‐ years 2000‐2011. http://www.who.int/healthinfo/global_burden_disease/en/ (accessed 8 April 2014). ">WHO 2013</a>). </p> <p>Exacerbations and comorbidities contribute to the variable natural history of COPD in individual patients (<a href="./references#CD001390-bbs2-0127" title="GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.com (accessed 2 July 2016). ">GOLD 2016</a>)<i>.</i> Exacerbations contribute to long‐term decline in lung function (<a href="./references#CD001390-bbs2-0122" title="DonaldsonGC , SeemungalTA , BhowmikA , WedzichaJA . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax2002;57(10):847‐52. ">Donaldson 2002</a>) and reduced physical activity (<a href="./references#CD001390-bbs2-0123" title="DonaldsonGC , WilkinsonTMA , HurstJR , PereraWR , WedzichaJA . Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2005;171:446‐52. ">Donaldson 2005</a><i>).</i> They have a profound and long‐lasting effect on quality of life (<a href="./references#CD001390-bbs2-0128" title="GroenewegenK , ScholsA , WoutersEFM . Prognosis after hospitalization for acute exacerbations of COPD. European Respiratory Journal2001;8(Suppl 33):209s. ">Groenewegen 2001</a>; <a href="./references#CD001390-bbs2-0149" title="SeemungalTAR , DonaldsonGC , PaulEA , BestallJC , JeffriesDJ , WedzichaJA . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157:1418‐22. ">Seemungal 1998</a>) and contribute to increased risk of death (<a href="./references#CD001390-bbs2-0153" title="Soler‐CatalunaJJ , Martinnez‐GarciaMA , Roman SanchezP , SalcedoE , NavarroM , OchandoR . Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax2005;60(11):925‐31. ">Soler‐Cataluna 2005</a>). Exacerbations are a major contributor to healthcare costs, especially for hospital admission (<a href="./references#CD001390-bbs2-0155" title="WedzichaJA , DonaldsonGC . Exacerbations of chronic obstructive pulmonary disease. Respiratory Care2003;48(12):1204‐15. ">Wedzicha 2003</a>). </p> <p>The clinical onset of an acute exacerbation is defined according to symptoms, although definitions vary (<a href="./references#CD001390-bbs2-0148" title="Rodriguez‐RoisinR . Toward a consensus definition for COPD exacerbations. Chest2000;117(90052):398S‐401S. ">Rodriguez‐Roisin 2000</a>). Anthonisen defined type 1 exacerbations on the basis of three major symptoms: increased dyspnoea, sputum volume and sputum purulence. Type 2 exacerbations required two major symptoms, and type 3 exacerbations required one major symptom plus cough, wheeze or symptoms of an upper respiratory tract infection (<a href="./references#CD001390-bbs2-0112" title="AnthonisenNR , ManfredaJ , WarrenCP , HershfieldES , HardingGK , NelsonNA . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine1987;106(2):196‐204. ">Anthonisen 1987</a>). A later definition required an increase in two 'major symptoms' of dyspnoea ‐ sputum volume and sputum purulence ‐ or an increase in one major symptom and in one 'minor symptom' for two days (wheeze, sore throat, cough or common cold symptoms) (<a href="./references#CD001390-bbs2-0150" title="SeemungalT , DonaldsonG , BhowmikA , JefriesD , WedizichaJ . Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161(5):1608‐13. ">Seemungal 2000</a>). Researchers recently developed a standardised measure for assessing the frequency, severity and duration of exacerbations of COPD using patient‐reported outcomes as described in clinical studies (<a href="./references#CD001390-bbs2-0133" title="LeidyNK , WilcoxTK , JonesPW , MurrayL , WinnetteR , HowardK , et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient‐reported outcome (PRO) measure. Value in Health2010;13(8):965‐75. ">Leidy 2010</a>). </p> <p>Patients with COPD with persistent lower airway bacterial colonisation when stable are at increased risk of exacerbations (<a href="./references#CD001390-bbs2-0113" title="BogaertD , Van derValkP , RamdinR , SluijterM , MonninkhofE , HendrixR , et al. Host‐pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infection and Immunity2004;72(2):818‐23. ">Bogaert 2004</a>; <a href="./references#CD001390-bbs2-0143" title="PatelIS , SeemungalTAR , WilksM , Lloyd‐OwenSJ , DonaldsonGC , WedzichaJA . Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax2002;57:759‐64. ">Patel 2002</a>). Infection is frequently detected during exacerbations; one study found that 48.4% of participants had viral causes and 54.7% had bacterial causes of infection (<a href="./references#CD001390-bbs2-0142" title="PapiA , BellettatoCM , BraccioniF , RomagnoliM , CasolariP , CaramoriG , et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American Journal of Respiratory &amp; Critical Care Medicine2006;173(10):1114‐21. ">Papi 2006</a>). Infection‐associated exacerbations required longer hospitalisation and resulted in greater impairment of lung function than exacerbations in which no infection was present (<a href="./references#CD001390-bbs2-0142" title="PapiA , BellettatoCM , BraccioniF , RomagnoliM , CasolariP , CaramoriG , et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American Journal of Respiratory &amp; Critical Care Medicine2006;173(10):1114‐21. ">Papi 2006</a>). Investigators in one study (<a href="./references#CD001390-bbs2-0143" title="PatelIS , SeemungalTAR , WilksM , Lloyd‐OwenSJ , DonaldsonGC , WedzichaJA . Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax2002;57:759‐64. ">Patel 2002</a>) recovered <i>Streptococcus pneumoniae</i> (<i>S pneumoniae</i>) from the sputum of 33% of participants. Risk of exacerbations of COPD is increased among patients with pneumococcal colonisation (<a href="./references#CD001390-bbs2-0113" title="BogaertD , Van derValkP , RamdinR , SluijterM , MonninkhofE , HendrixR , et al. Host‐pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infection and Immunity2004;72(2):818‐23. ">Bogaert 2004</a>). Researchers have discovered an association between detection of <i>S pneumoniae</i> as a new organism in the sputum of patients with COPD and significantly increased risk of an exacerbation (<a href="./references#CD001390-bbs2-0151" title="SethiS , EvansN , GrantBJB , MurphyTF . New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine2002;347(7):465‐71. ">Sethi 2002</a>). </p> <p>Pneumonia is usually a serious illness, and diagnosis is based on the presence of radiological infiltrates, symptoms (cough, expectoration, fever, dyspnoea, pleuritic pain, altered mental status), signs of pulmonary consolidation on auscultation and leukocytosis (<a href="./references#CD001390-bbs2-0078" title="Ochoa‐GondarO , Vila‐CorcolesA , AnsaX , Rodriguez‐BlancoT , SalsenchE , deDiegoC , et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN‐65 study. Vaccine2008;26(16):1955‐62. Ochoa‐GondarO , Vila‐CorcolesA , deDiegoC , ArijaV , MaxenchsM , GriveM , et al. The burden of community‐acquired pneumonia in the elderly: the Spanish EVAN‐65 Study. BMC Public Health2008;8(1):222. ">Ochoa‐Gondar 2008</a>). Community‐acquired pneumonia (CAP) is a major health problem among adults over 65 years of age (<a href="./references#CD001390-bbs2-0156" title="WelteT , KohnleinT . Global and local epidemiology of community‐acquired pneumonia: the experience of the CAPNETZ Network. Seminars in Respiratory and Critical Care Medicine2009;30(2):127‐35. ">Welte 2009</a>), and prevalence of 14 cases per 1000 person‐years (95% confidence interval (CI) 12.7 to 15.3) has been reported. Hospitalisation rate is high (75%), and in‐patient stays are often lengthy (mean 10.4 days) (<a href="./references#CD001390-bbs2-0078" title="Ochoa‐GondarO , Vila‐CorcolesA , AnsaX , Rodriguez‐BlancoT , SalsenchE , deDiegoC , et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN‐65 study. Vaccine2008;26(16):1955‐62. Ochoa‐GondarO , Vila‐CorcolesA , deDiegoC , ArijaV , MaxenchsM , GriveM , et al. The burden of community‐acquired pneumonia in the elderly: the Spanish EVAN‐65 Study. BMC Public Health2008;8(1):222. ">Ochoa‐Gondar 2008</a>). Overall mortality estimates are high: 6% in Canada, 20% in the USA and Spain, 13% in the UK and 8% in Sweden (<a href="./references#CD001390-bbs2-0125" title="FileTMJr . Community‐acquired pneumonia. The Lancet2003;362(9400):1991‐2001. ">File 2003</a>; <a href="./references#CD001390-bbs2-0135" title="MandellLA , WunderinkRG , AnzuetoA , BartlettJG , CampbellGD , DeanNC , et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community‐acquired pneumonia in adults. Clinical Infectious Diseases2007;44(Suppl 2):S27‐72. ">Mandell 2007</a>). Patients with COPD who develop CAP have more severe pneumonia, are admitted to the intensive care unit more frequently and have significantly higher 30‐ and 90‐day mortality than non‐COPD patients (<a href="./references#CD001390-bbs2-0137" title="MolinosL , ClementeMG , MirandaB , AlvarezC , delBustoB , CocinaBR , et al. Community‐acquired pneumonia in patients with and without chronic obstructive pulmonary disease. Journal of Infection2009;58(6):417‐24. ">Molinos 2009</a>; <a href="./references#CD001390-bbs2-0145" title="RestrepoMI , MortensenEM , PughJA , AnzuetoA . COPD is associated with increased mortality in patients with community‐acquired pneumonia. European Respiratory Journal2006;28(2):346‐51. ">Restrepo 2006</a>). <i>S pneumoniae</i> is the predominant pathogen among all patients with CAP (<a href="./references#CD001390-bbs2-0135" title="MandellLA , WunderinkRG , AnzuetoA , BartlettJG , CampbellGD , DeanNC , et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community‐acquired pneumonia in adults. Clinical Infectious Diseases2007;44(Suppl 2):S27‐72. ">Mandell 2007</a>) and among patients with COPD and CAP, for whom a 43% pneumococcal aetiology has been found (<a href="./references#CD001390-bbs2-0134" title="LiebermanD , GelferY , VarshavskyR , DvoskinB , LeinonenM , FriedmanMG . Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest2002;122(4):1264‐70. ">Lieberman 2002</a>; <a href="./references#CD001390-bbs2-0154" title="TorresA , DorcaJ , ZalacainR , BelloS , El‐EbiaryM , MolinosL , et al. Community‐acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. American Journal of Respiratory and Critical Care Medicine1996;154(5):1456‐61. ">Torres 1996</a>). Progression from COPD to CAP has been shown to be strongly associated with the presence of <i>S pneumoniae</i> (57.3%), and other pathogens were predominant among exacerbations that did not progress to CAP (61.7%) (<a href="./references#CD001390-bbs2-0126" title="FileTMJr , MonteSV , SchentagJJ , PaladinoJA , KlugmanKP , LavinB , et al. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community‐acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. International Journal of Antimicrobial Agents2009;33(1):58‐64. ">File 2009</a>). </p> </section> <section id="CD001390-sec-0025"> <h3 class="title" id="CD001390-sec-0025">Description of the intervention</h3> <p>On the basis of differences in polysaccharide capsules, investigators have identified 91 different serotypes of <i>S pneumoniae.</i> Capsule polysaccharides have antiphagocytic activity, which affects the pathogenesis of invasive pneumococcal disease (IPD), including CAP (<a href="./references#CD001390-bbs2-0144" title="PostmaDF , vanWerkhovenCH , HuijtsSM , BolkenbaasM , OosterheertJJ , BontenMJ . New trends in the prevention and management of community‐acquired pneumonia. Netherlands Journal of Medicine2012;70(8):337‐48. ">Postma 2012</a>), and the incidence of IPD differs between serotypes. In the late 1970s, a 14‐valent pneumococcal polysaccharide vaccine (PPV‐14) was registered in the United States; this was replaced in the 1980s by a 23‐valent pneumococcal polysaccharide vaccine (PPV‐23) (Pneumovax/Pneumo 23) in the USA and Europe. This vaccine contains purified capsular antigens from 23 serotypes that cover 85% to 90% of cases of invasive pneumococcal disease among adults (<a href="./references#CD001390-bbs2-0124" title="European Respiratory Society. Immunisation against respiratory diseases. http://www.erswhitebook.org/chapters/immunisation‐against‐respiratory‐diseases/streptococcus‐pneumoniae/ (accessed 25 November 2014). ">ERS 2014</a>). The vaccine induces T‐cell‐independent short‐lived B‐cell immune responses by causing B cells to differentiate into plasma cells, producing antibodies without producing memory B cells. The immunological antibody response is age‐ and serotype‐dependent and generally is lower among elderly people than in younger adults. A booster vaccination produces no memory response. </p> <p>To enhance the immunogenicity of pneumococcal vaccines, researchers have developed conjugate vaccines. Polysaccharide antigens are chemically joined to a highly immunogenic protein carrier (such as tetanus or diphtheria toxoid). This process leads to the induction of B cell‐dependent and T cell‐dependent responses as well as a memory response to a booster dose of the vaccine. Healthcare providers have administered pneumococcal conjugate vaccine containing capsular polysaccharides from seven pneumococcal serotypes (PCV‐7) to young children since the 2000s, with a resulting striking decrease in invasive pneumococcal disease caused by vaccine serotypes. As children are the main reservoir of <i>S pneumoniae</i> (60% are carriers), a reduction in the carrier rate has had beneficial effects among children and a protective herd effect in adults (<a href="./references#CD001390-bbs2-0138" title="MoseleyAM , DransfieldMT . Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies. Clinical Investigation2013;3(9):887‐97. ">Moseley 2013</a>). </p> <p>Investigators are evaluating new conjugate vaccines, including 7‐valent (PCV‐7), 10‐valent (PCV‐10) and 13‐valent (PCV‐13) vaccines, for use in children and adults, although respiratory guidelines in Europe (<a href="./references#CD001390-bbs2-0124" title="European Respiratory Society. Immunisation against respiratory diseases. http://www.erswhitebook.org/chapters/immunisation‐against‐respiratory‐diseases/streptococcus‐pneumoniae/ (accessed 25 November 2014). ">ERS 2014</a>) and Australia (<a href="./references#CD001390-bbs2-0121" title="COPD Guidelines Steering Committee. The COPD‐X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease, March 2016. http://www.copdx.org.au/ (accessed 2 July 2016). ">COPDX 2016</a>) recommend immunisation with the PPV‐23 polysaccharide pneumococcal vaccine for adults at risk of pneumococcal disease, including those with COPD. The PCV‐13 and the PCV‐10 are not recommended for patients with COPD in Australia (<a href="./references#CD001390-bbs2-0139" title="NHMRC: Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th Edition. Canberra: Australian Government Department of Health, 2013. ">NHMRC 2013</a>). Recommendations for age at immunisation and at revaccination vary depending on the guideline, with some recommending vaccination only for patients who are over 64 years of age, or for younger patients with severe COPD or comorbid conditions (<a href="./references#CD001390-bbs2-0127" title="GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.com (accessed 2 July 2016). ">GOLD 2016</a>), and others recommending vaccination for all patients 50 years of age and older, along with revaccination five years later (<a href="./references#CD001390-bbs2-0139" title="NHMRC: Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th Edition. Canberra: Australian Government Department of Health, 2013. ">NHMRC 2013</a>). </p> </section> <section id="CD001390-sec-0026"> <h3 class="title" id="CD001390-sec-0026">How the intervention might work</h3> <p>Patients with COPD are able to mount a significant immune response to pneumococcal infection (<a href="./references#CD001390-bbs2-0113" title="BogaertD , Van derValkP , RamdinR , SluijterM , MonninkhofE , HendrixR , et al. Host‐pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infection and Immunity2004;72(2):818‐23. ">Bogaert 2004</a>); thus immunisation against pneumococcal infection may be effective in preventing bacterial growth in the airways of patients with COPD, in turn decreasing the occurrence of exacerbations and pneumonia. </p> </section> <section id="CD001390-sec-0027"> <h3 class="title" id="CD001390-sec-0027">Why it is important to do this review</h3> <p>Major COPD guidelines (<a href="./references#CD001390-bbs2-0121" title="COPD Guidelines Steering Committee. The COPD‐X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease, March 2016. http://www.copdx.org.au/ (accessed 2 July 2016). ">COPDX 2016</a>; <a href="./references#CD001390-bbs2-0124" title="European Respiratory Society. Immunisation against respiratory diseases. http://www.erswhitebook.org/chapters/immunisation‐against‐respiratory‐diseases/streptococcus‐pneumoniae/ (accessed 25 November 2014). ">ERS 2014</a>; <a href="./references#CD001390-bbs2-0127" title="GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.com (accessed 2 July 2016). ">GOLD 2016</a>; <a href="./references#CD001390-bbs2-0141" title="National Clinical Guideline Centre. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre, 2010. www.nice.org.uk/guidance/cg101. ">NICE 2010</a>) have recommended pneumococcal vaccination, largely on the basis of results showing the efficacy of pneumococcal vaccination as reported by observational studies in general populations and by randomised controlled trials (RCTs) in people without COPD. Both a large indirect cohort study (<a href="./references#CD001390-bbs2-0022" title="ButlerJC , BreimanRF , CampbellJF , LipmanHB , BroomeC , FacklamRR . Pneumococcal polysaccharide vaccine efficacy. JAMA1993;270:1826‐31. ">Butler 1993</a>) and a meta‐analysis (<a href="./references#CD001390-bbs2-0038" title="FineMJ , SmithMA , CarsonCA , MeffeF , SnakeySS , WeissfeldLA , et al. Efficacy of pneumococcal vaccination in adults. A meta‐analysis of randomized controlled trials. Archives of Internal Medicine1994;154(23):2666‐77. ">Fine 1994</a>) of pneumococcal vaccination have confirmed protection against invasive bacteraemic disease, but efficacy remains to be assessed in the population with COPD, for which risks of CAP and of deterioration may be higher owing to exacerbations of the disease. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001390-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001390-sec-0028"></div> <p>To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001390-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001390-sec-0029"></div> <section id="CD001390-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001390-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included in this review only RCTs using injectable pneumococcal vaccines.</p> </section> <section id="CD001390-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies if participants were adults with a diagnosis of COPD, preferably based on objective diagnostic criteria: demonstration of airflow obstruction on spirometry, generally forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC) ratio less than 0.7 (<a href="./references#CD001390-bbs2-0127" title="GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.com (accessed 2 July 2016). ">GOLD 2016</a>) and a significant smoking history. We included studies in which the proportion of participants with COPD was at least 80%, if the age of other participants matched that of participants with COPD. </p> </section> <section id="CD001390-sec-0033"> <h4 class="title">Types of interventions</h4> <p>At least one injectable pneumococcal vaccine ‐ a pneumococcal polysaccharide vaccine or a pneumococcal conjugate vaccine or other vaccine type. The control group could be given placebo or no vaccination, or different types of pneumococcal vaccine for comparison. </p> </section> <section id="CD001390-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD001390-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001390-list-0001"> <li> <p>Pneumonia</p> </li> <li> <p>Mortality, respiratory‐related and all‐cause</p> </li> <li> <p>Healthcare utilisation, including hospital admissions and emergency department visits</p> </li> </ol> </p> </section> <section id="CD001390-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001390-list-0002"> <li> <p>Acute exacerbations of COPD</p> </li> <li> <p>Days of disability from respiratory illness variously defined as days in bed, days off work or days when the participant was unable to undertake normal activities </p> </li> <li> <p>Lung function</p> </li> <li> <p>Adverse effects of vaccination</p> </li> <li> <p>Cost‐effectiveness of pneumococcal vaccination</p> </li> <li> <p>Quality of life</p> </li> </ol> </p> </section> </section> </section> <section id="CD001390-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001390-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Airways Specialised Register up to 25 November 2016. The Information Specialist for the Group maintains the Cochrane Airways Specialised Register, which contains studies identified from several sources. </p> <p> <ol id="CD001390-list-0003"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies Online (CRSO) (http://crso.cochrane.org/). </p> </li> <li> <p>Weekly searches of MEDLINE Ovid SP.</p> </li> <li> <p>Weekly searches of Embase Ovid SP.</p> </li> <li> <p>Monthly searches of PsycINFO Ovid SP.</p> </li> <li> <p>Monthly searches of the Cumulative Index to Nursing and Allied Health Literature (CINAHL) EBSCO. </p> </li> <li> <p>Monthly searches of Allied and Complementary Medicine (AMED) EBSCO.</p> </li> <li> <p>Handsearches of the proceedings of major respiratory conferences.</p> </li> </ol> </p> <p>We identified studies included in the Trials Register by applying search strategies based on the scope of the Cochrane Airways Review Group. We have provided details of these strategies, as well as a list of handsearched conference proceedings, in <a href="./appendices#CD001390-sec-0095">Appendix 1</a>. See <a href="./appendices#CD001390-sec-0101">Appendix 2</a> for search terms used to identify studies for this review. </p> <p>We carried out additional searches of CENTRAL CRSO (searched 25 November 2016), MEDLINE Ovid (1946 to 23 November 2016) and Embase Ovid (1974 to 23 November 2016). We have listed in <a href="./appendices#CD001390-sec-0102">Appendix 3</a> the search strategies used for these databases. We applied no restrictions on language of publication. </p> </section> <section id="CD001390-sec-0039"> <h4 class="title">Searching other resources</h4> <p>From full‐text papers obtained, we searched the bibliographic lists for additional articles. We also conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) and the World Health Organization (WHO) trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) up to 25 November 2016 and pharmaceutical company clinical trial databases of companies manufacturing pneumococcal vaccines. </p> </section> </section> <section id="CD001390-sec-0040"> <h3 class="title" id="CD001390-sec-0040">Data collection and analysis</h3> <section id="CD001390-sec-0041"> <h4 class="title">Selection of studies</h4> <p>At least two review authors (JW, JT or RWB) assessed all potentially relevant trials for relevance by screening the full texts to independently select studies for inclusion and identified and recorded reasons for exclusion of ineligible studies. We resolved disagreements through discussion or, if required, we consulted a third review author. We identified and excluded duplicates and collated multiple reports of the same study, so that each study (rather than each report) was the unit of interest in the review. We recorded the selection process via a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) flow diagram (<a href="#CD001390-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD001390-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001390-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001390-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JT, JW) independently extracted study details and used a data collection form to record the following study characteristics and outcome data. </p> <p> <ol id="CD001390-list-0004"> <li> <p>Methods: study design, total duration of study, number of study centres and locations, study setting, duration and date of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, withdrawals, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: study treatment, comparison, cointerventions.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points reported.</p> </li> <li> <p>Notes: funding for trial, trial registration, notable conflicts of interest of trial authors. </p> </li> </ol> </p> <p>The first review author entered data into Review Manager (version 5.3) (<a href="./references#CD001390-bbs2-0146" title="The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and a second review author double‐checked the data. We checked that data were entered correctly by comparing data presented in the systematic review against information provided in the study reports. </p> </section> <section id="CD001390-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias for each study (JW, JT), using criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001390-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Cochrane Handbook</a>). We resolved disagreements by discussion or by consultation with another review author. We assessed risk of bias according to the following domains. </p> <p> <ol id="CD001390-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias(es).</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report, together with a justification for our judgement, in the 'Risk of bias' table. We summarised risk of bias judgements across different studies for each of the domains listed. When information on risk of bias was related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for studies that contributed to those outcomes. </p> </section> <section id="CD001390-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous outcomes by using Mantel‐Haenszel odds ratios (ORs) with 95% confidence intervals (CIs). When events were rare, we employed the Peto odds ratio. We entered scale data with a consistent direction of effect.<br/> <br/> For continuous variables, we analysed data as mean differences (MDs) with 95% CIs. We used standardised mean differences (SMDs) with 95% CIs if investigators had used different scales of measurement for a specific outcome. The SMD is a statistic that expresses differences in means between treatment groups in units of the pooled standard deviation. </p> <p>We undertook meta‐analyses only when this was meaningful, that is, when treatments, participants and the underlying clinical question were similar. </p> <p>When skewed data were available (reported as medians and interquartile ranges), we described them narratively. </p> <p>For 'time‐to‐event' outcomes such as log hazard ratios, we used the fixed‐effect generic inverse variance outcome to combine results. This method yields a weighted average of effect estimates of separate studies (<a href="./references#CD001390-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Cochrane Handbook</a>, Chapter 9). We calculated the number needed to treat for an additional beneficial outcome from the pooled OR and its CI, using baseline risk in the control group. </p> </section> <section id="CD001390-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We used participants as the unit of analysis when analysing dichotomous data.</p> </section> <section id="CD001390-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators to obtain missing numerical outcome data when possible (e.g. when a study was identified as abstract only).<br/> <br/> When this was not possible, and missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by performing a sensitivity analysis<b>.</b> </p> </section> <section id="CD001390-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used a Breslow‐Day test to assess heterogeneity for pooled effects when the null hypothesis was that all studies were evaluating the same effect; we considered a P value &gt; 0.05 to indicate significant differences between studies.<br/> In addition, we used the I<sup>2</sup> statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than to chance (<a href="./references#CD001390-bbs2-0130" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>). We interpreted statistical heterogeneity as follows: 0% to 40% might not be important, 30% to 60% may represent moderate heterogeneity and 50% to 90% may represent substantial heterogeneity (<a href="./references#CD001390-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Cochrane Handbook</a>). </p> <p>We assessed clinical and methodological heterogeneity by recording differences in study design and participant characteristics between individual studies. When we found substantial heterogeneity. we reported this and explored possible causes by conducting prespecified subgroup analyses. </p> </section> <section id="CD001390-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to minimise reporting bias resulting from non‐publication of studies or from selective outcome reporting by using a broad search strategy, checking references of included studies and relevant systematic reviews and contacting study authors to ask for additional outcome data. We visually inspected funnel plots when 10 or more studies contributed to the analysis for a specific outcome. </p> </section> <section id="CD001390-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We combined studies to compare the following.</p> <p> <ol id="CD001390-list-0006"> <li> <p>Comparison 1: pneumococcal polysaccharide vaccine, 23‐valent (PPSV‐23) OR 14‐valent (PPV‐14), versus control. </p> </li> <li> <p>Comparison 2: 23‐valent pneumococcal polysaccharide vaccine (PPV‐23) versus 7‐valent diphtheria‐conjugated pneumococcal polysaccharide vaccine (PCV‐7). </p> </li> </ol> </p> <p>We used a fixed‐effect model, but we performed a sensitivity analysis by using a random‐effects model if we detected unexplained heterogeneity. We presented the findings of our primary outcomes in a 'Summary of findings' table according to recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001390-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Cochrane Handbook</a>) (generated with the use of GradePro software). </p> </section> <section id="CD001390-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If heterogeneity was not sufficiently accounted for by study quality, we specified the following subgroup analyses a priori. </p> <p> <ol id="CD001390-list-0007"> <li> <p>Vaccine type ‐ the number of capsular polysaccharide antigens used in the vaccine (more than 14 vs 14 or fewer). </p> </li> <li> <p>Severity of COPD (assessed by lung function: mild = FEV<sub>1</sub> 50% to 79% predicted, moderate = FEV<sub>1</sub> 35% to 49% predicted, severe = FEV<sub>1</sub>&lt; 35% predicted). </p> </li> <li> <p>Setting of the study.</p> </li> <li> <p>Match between strain of vaccine and infecting strains.</p> </li> <li> <p>Age of participants.</p> </li> </ol> </p> </section> <section id="CD001390-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>In assessing heterogeneity, we considered possible causes associated with details of study design.<br/> <br/> We performed sensitivity analyses using random‐effects models versus a fixed‐effect model to examine risk of bias and other potential confounders, and to evaluate studies published only as abstracts. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001390-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001390-sec-0052"></div> <section id="CD001390-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD001390-sec-0054"> <h4 class="title">Results of the search</h4> <p>From searches for the original 2004 review, we included two studies (<a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>), and in 2010, we included five additional studies (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a> (published conference abstract); <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a> (published conference abstract)). Through searches conducted for this 2016 review (current to 25 November 2016) (<a href="#CD001390-fig-0002">Figure 2</a>), we identified 157 unique new citations, assessed 20 for eligibility, and added five to this review (<a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a> (published conference abstract); <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>). </p> <p>We have listed the reasons for exclusion of studies in the <a href="./references#CD001390-sec-0121" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD001390-sec-0055"> <h4 class="title">Included studies</h4> <p>For specific details of each study included in the review, see the <a href="./references#CD001390-sec-0120" title="">Characteristics of included studies</a> table. </p> <p>We included in this review 12 RCTs of pneumococcal vaccines for a total of 2171 participants that provided outcome data for COPD. When studies included participants with other diagnoses, such as <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>, we included only data for participants with COPD. Average duration of follow‐up was 14 months. Two studies (<a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>) reported follow‐up for six months; three studies (<a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>) follow‐up for 12 months; four studies (<a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>) follow‐up for 24 months; two studies (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>) follow‐up for 32 months and one study (<a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>) follow‐up for 48 months. </p> <section id="CD001390-sec-0056"> <h5 class="title">Study setting and participants</h5> <p>All studies were conducted in a community setting and were randomised, parallel‐group trials (<a href="#CD001390-tbl-0002">Table 1</a>). Participants (n = 2171) had a diagnosis of COPD that was based on spirometric criteria (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>);clinical or spirometric criteria (<a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>); a clinical diagnosis of COPD (<a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>); or a diagnosis not specified (<a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>). A common exclusion criterion was previous pneumococcal vaccination. The average age of study participants was 66 years, and the percentage of male participants was 67%(range 36% to 98%). When data could be extracted, the mean FEV<sub>1</sub> was 1.2 L (five studies), 54% of predicted (four studies). Information on participants’ treatment with inhaled corticosteroids was available only for <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a> (65%) and <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a> (100%); in <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>, 24% of participants were taking oral corticosteroids. </p> <div class="table" id="CD001390-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting/Follow‐up, months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age/% male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean FEV<sub>1</sub> (L) or % predicted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% AE 12 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% prior pneumonia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% current smokers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a> (n = 600) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seville, Spain/32 median</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 ± 0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a> (n = 103) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14‐valent PPV 0.5 mL SC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline 0.5 mL SC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New York, USA/24 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63/NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 ± 0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a> (n = 181) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐valent PCV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA 21 centres/48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64/37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> (n = 55 with COPD ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14‐valent PPV + influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kyushu &amp; Okinawa, Japan/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a> (Russian paper) (n = 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Russia/12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30‐70/36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a> (n = 189) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14‐valent PPV + influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline + influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montreal Canada/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 ± 0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a> (abstract &amp; poster) (n = 36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taipei, Taiwan/12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71/89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1% to 45%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (&gt; 1500 mcg/d)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a> (n = 49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV 0.5 mL SC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65‐72/55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 to 1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OCS 24%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a> (Abstract) (n = 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a> (Russian paper) (n = 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Russia/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a> (abstract) (n = 373) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Russia/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OCS not allowed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a> (abstract &amp; unpublished paper) (n = 144) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey &amp; UK/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65/93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 L ± 0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE = acute exacerbation of COPD.</p> <p>ICS = inhaled corticosteroids.</p> <p>OCS = oral corticosteroids.</p> <p>PCV = diphtheria‐conjugated pneumococcal polysaccharide vaccine.</p> <p>PPV = pneumococcal polysaccharide vaccine.</p> </div> </div> </section> <section id="CD001390-sec-0057"> <h5 class="title">Intervention and comparison</h5> </section> <section id="CD001390-sec-0058"> <h5 class="title">Vaccine type</h5> <p>Investigators used a 23‐valent pneumococcal polysaccharide vaccine in <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>, <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>, <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>, <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>, <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>, <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>, <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>, <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a> and <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>, and a 14‐valent pneumococcal polysaccharide vaccine in <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>, <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> and <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>. </p> <p>Treatment groups in <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a> and <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> also received influenza vaccine. </p> </section> <section id="CD001390-sec-0059"> <h5 class="title">Comparison</h5> <p>Control groups in <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a> and <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> received the same influenza vaccine as the intervention group. </p> <p>Control groups in <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>, <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a> and <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a> received a placebo injection. </p> <p>Researchers in <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>, <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>, <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>, <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>, <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a> and <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>, withheld vaccine from the control group and did not administer a placebo. </p> <p><a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a> used a different vaccine in the comparison group ‐ a 7‐valent diphtheria‐conjugated pneumococcal polysaccharide vaccine. </p> <p>In all studies, investigators administered injections subcutaneously.</p> <section id="CD001390-sec-0060"> <h6 class="title">Outcome measurement</h6> <p>Eight studies reported data on participants experiencing one or more episodes of pneumonia ‐ but not all episodes were confirmed as due to pneumococcal infection (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>; <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>). The basis for the diagnosis of pneumonia was radiological AND included clinical symptoms/signs in <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>, <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>, <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a> and <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; was radiological OR included clinical symptoms/signs in <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> and <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; and was self‐reported by participants in <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>. </p> </section> </section> </section> <section id="CD001390-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Of 100 excluded citations, 35 were reviews/commentary articles, 41 were not of RCT design, 18 included non‐COPD participants or did not provide their data separately and six provided an intervention that was not an injectable pneumococcal vaccine. Individual reasons for exclusion of studies are listed in the <a href="./references#CD001390-sec-0121" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD001390-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>Review authors assessed the quality of the 12 studies included in the review against six criteria and provide a summary of results in <a href="#CD001390-fig-0003">Figure 3</a> and <a href="#CD001390-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD001390-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD001390-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD001390-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD001390-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD001390-sec-0063"> <h4 class="title">Allocation</h4> <section id="CD001390-sec-0064"> <h5 class="title">Allocation generation</h5> <p>Overall risk of selection bias due to allocation generation was moderate. Six of the 12 studies did not report their methods for random sequence generation (<a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>). All of the remaining trials had low risk of bias. Methods for random sequence generation varied by study. Four studies used random number tables, one performed random number generation in blocks of 10 (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>) and another conducted randomisation centrally online (<a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>). </p> </section> <section id="CD001390-sec-0065"> <h5 class="title">Allocation concealment</h5> <p>Overall risk of selection bias due to allocation concealment was moderate. However, nine of the 12 studies did not report their methods for allocation concealment (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>). The remaining three had low risk of bias. Allocation concealment methods included third party randomisation and sequentially numbered, opaque, sealed envelopes. </p> </section> </section> <section id="CD001390-sec-0066"> <h4 class="title">Blinding</h4> <p>Overall risk of performance bias and detection bias was moderate, with three studies at particularly high risk of bias (<a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>). Two had low risk of bias (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>), and nine could not be adequately assessed for risk. </p> <p>Of the 12 studies, two were double‐blind (<a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>), three were single‐blind (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>), two were open‐label (<a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>) and five did not describe the use of blinding. Among double‐blind trials, only <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a> adequately described the method of blinding used. Of three single‐blind trials, <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a> blinded participants, <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a> blinded assessors and <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a> did not indicate who was blinded. We could not perform sensitivity analysis for <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>, as it was the only study that compared PPSV‐23 versus PCV‐7. However, sensitivity analysis for the outcome of acute COPD exacerbation for <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a> showed little change in the direction of effect. </p> <p>Six of the 12 studies (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>) did not use any form of placebo; <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a> used PCV‐7 as a comparator. Sensitivity analysis for the primary outcome of pneumonia with exclusion of these studies showed a shift in effect direction, although the OR remained of no statistical significance (OR 0.78, 95% CI 0.16 to 3.68). For acute exacerbations of COPD, data showed no shift in effect direction nor in OR significance, with a wider CI (OR 0.41, 95% CI 0.18 to 0.92). We noted similar findings for all‐cause mortality (OR 0.95, 95% CI 0.48 to 1.86) and all‐cause hospital admissions (OR 0.80, 95% CI 0.21 to 3.13). </p> </section> <section id="CD001390-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>Overall risk of attrition bias was low. Six of the 12 studies managed to adequately address incomplete outcomes, with no unequal rates across groups and with adequate reasons provided for drop‐outs and losses to follow‐up (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>; <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>). </p> </section> <section id="CD001390-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Overall risk of reporting bias was very low. Nine of the 12 studies adequately addressed all primary and secondary outcomes (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>; <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>). </p> </section> <section id="CD001390-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>Of the 12 studies, 11 did not display other types of bias (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>; <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>). The only study that displayed unclear risk was <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>. As this study relied in part on self‐reported vaccination, some participants may have been misclassified as vaccine‐naive or previously vaccinated; or may have been enrolled within five years after the previous vaccination dose. </p> </section> </section> <section id="CD001390-sec-0070"> <h3 class="title" id="CD001390-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD001390-tbl-0001"><b>Summary of findings for the main comparison</b> Pneumoccocal vaccination to prevent pneumonia in chronic obstructive pulmonary disease?</a> </p> <section id="CD001390-sec-0071"> <h4 class="title">Comparison 1: pneumococcal polysaccharide vaccine, 23‐valent (PPSV‐23) OR 14‐valent (PPV‐14), versus control (11 studies; N = 2125) </h4> <section id="CD001390-sec-0072"> <h5 class="title">Primary outcomes</h5> <section id="CD001390-sec-0073"> <h6 class="title">Pneumonia</h6> <p><a href="./references#CD001390-fig-0008" title="">Analysis 1.1</a>: likelihood of at least one episode of community‐acquired pneumonia (CAP): We found six relevant studies (n = 1372) with follow‐up ranging from six to 36 months. Results showed a statistically significant difference with lower likelihood for vaccine compared with control (subgrouped by vaccine number of serotypes) (OR 0.59, 95% 0.41 to 0.85) and no heterogeneity (<a href="#CD001390-fig-0005">Figure 5</a>). Subgroup analysis of likelihood of CAP by lung function was possible only with data from <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a> (<a href="./references#CD001390-fig-0027" title="">Analysis 3.1</a>) for participants with FEV<sub>1</sub> &lt; 40% predicted at baseline (OR 0.48, 95% CI 0.23 to 1.00) and for participants with FEV<sub>1</sub> ≥ 40% predicted (OR 1.12, 95% CI 0.50 to 2.48). A test for subgroup differences was not statistically significant: Chi² = 2.36, df = 1 (P = 0.12), I² = 57.6%. </p> <div class="figure" id="CD001390-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 Community‐acquired pneumonia: at least 1 episode." data-id="CD001390-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 Community‐acquired pneumonia: at least 1 episode. </p> </div> </div> </div> <p><a href="./references#CD001390-fig-0009" title="">Analysis 1.2</a>: rate of CAP per person‐year: For this outcome, we found one relevant trial with 12 months of follow up (n = 36). Investigators reported no significant differences between vaccine and control groups (risk ratio (RR) 0.37, 95% CI 0.12 to 1.14). </p> <p><a href="./references#CD001390-fig-0010" title="">Analysis 1.3</a>: likelihood of at least one episode of pneumococcal pneumonia: We found three relevant trials with follow‐up ranging from six to 36 months (n = 1158). Results showed no significant differences between vaccine and control groups (subgrouped by vaccine number of serotypes) (Peto OR 0.26, 95% CI 0.05 to 1.31) (<a href="#CD001390-fig-0006">Figure 6</a>). Heterogeneity was substantial: Chi² = 3.44, df = 1 (P = 0.06), I² = 71%; and the test for subgroup differences approached significance: Chi² = 3.44, df = 1 (P = 0.06), I² = 70.9%. </p> <div class="figure" id="CD001390-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.4 Death from cardiorespiratory causes." data-id="CD001390-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.4 Death from cardiorespiratory causes. </p> </div> </div> </div> </section> <section id="CD001390-sec-0074"> <h6 class="title">Mortality</h6> <p><a href="./references#CD001390-fig-0011" title="">Analysis 1.4</a>: death from cardiorespiratory causes: We found three relevant studies, with follow‐up ranging from 24 to 48 months (n = 888). Results showed no significant differences in likelihood between vaccine and control groups (subgrouped by vaccine number of serotypes) (OR 1.07, 95%CI 0.69 to 1.66) (<a href="#CD001390-fig-0006">Figure 6</a>) and no heterogeneity. </p> <p><a href="./references#CD001390-fig-0012" title="">Analysis 1.5</a>: death from all causes: We found five relevant trials with follow‐up ranging from 12 to 48 months (n = 1053). Results revealed no significant differences in likelihood between vaccine and control groups (subgrouped by vaccine number of serotypes) (OR 1.00, 95% CI 0.72 to 1.40) and no heterogeneity. </p> </section> <section id="CD001390-sec-0075"> <h6 class="title">Healthcare utilisation</h6> <p><a href="./references#CD001390-fig-0013" title="">Analysis 1.6</a>: likelihood of at least one episode of hospital admission for any cause: We found three relevant studies with follow‐up ranging from three to 12 months (n = 391). Results showed no significant differences in likelihood between vaccine and control groups (OR 0.74, 95% CI 0.32 to 1.74) and no heterogeneity. When we included the 24‐month follow‐up period for <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>, which was affected by a greater number of withdrawals (<a href="./references#CD001390-fig-0028" title="">Analysis 3.2</a>), the result was similar (OR 0.54, 95% 0.23 to 1.22). </p> <p><a href="./references#CD001390-fig-0014" title="">Analysis 1.7</a>: rate of cardiorespiratory‐related hospital admissions: We found one relevant study (<a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; n = 160) that reported no significant differences between vaccine and control groups for follow‐up between seven and 12 months (RR 0.89, 95% CI 0.51 to 1.58) nor any differences for longer follow‐up periods of 13 to 18 months and 19 to 24 months (<a href="./references#CD001390-fig-0029" title="">Analysis 3.3</a>). </p> <p><a href="./references#CD001390-fig-0015" title="">Analysis 1.8</a>: rate of all‐cause hospital admissions: We found one relevant study with 12 months of follow‐up (n = 36). Results showed no significant differences between vaccine and control groups (RR 0.84, 95% CI 0.26 to 2.71). </p> <p><a href="./references#CD001390-fig-0016" title="">Analysis 1.9</a>: likelihood of at least one emergency department (ED) visit for any cause: We found one relevant study (<a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>) with follow‐up between three and 12 months (n = 142). Results showed statistically significant differences, with lower likelihood for vaccine compared with control (OR 0.26, 95% CI 0.07 to 0.91); results for a long‐term follow‐up period of 12 to 24 months were similar (<a href="./references#CD001390-fig-0030" title="">Analysis 3.4</a>). Another single study (<a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>) reported ED visits due to respiratory causes, upper respiratory tract infection (URTI), lower respiratory tract infection (LRTI) and pneumonia and described no significant differences with vaccination (<a href="./references#CD001390-fig-0031" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD001390-sec-0076"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD001390-fig-0017" title="">Analysis 1.10</a>: likelihood of at least one episode of COPD exacerbation: For this outcome, we found four relevant studies (n = 446), with varying durations of follow‐up: six months for <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>, 12 months for <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a> and <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a> and 24 months for <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>. Results showed a statistically significant difference with lower likelihood for vaccine than for control (OR 0.60, 95% CI 0.39 to 0.93) (<a href="#CD001390-fig-0007">Figure 7</a> and <a href="./full#CD001390-fig-0001">Figure 1</a>), with no heterogeneity. When we used the 24‐month follow‐up period for <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>, which was affected by a greater number of withdrawals, the result was similar (<a href="./references#CD001390-fig-0032" title="">Analysis 3.6</a>) but showed greater heterogeneity (OR 0.53, 95% CI0.34 to 0.81; Chi² = 5.66, df = 3 (P = 0.13), I² = 47%). </p> <div class="figure" id="CD001390-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 At least 1 COPD exacerbation." data-id="CD001390-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 At least 1 COPD exacerbation. </p> </div> </div> </div> <p><a href="./references#CD001390-fig-0018" title="">Analysis 1.11</a>: COPD exacerbations: For this outcome, we found one relevant study with six months of follow‐up (n = 373). Results showed a significant difference between vaccine and control groups (mean difference (MD) ‐0.59 episodes, 95% CI ‐0.80 to ‐0.38). </p> <p><a href="./references#CD001390-fig-0019" title="">Analysis 1.12</a>: rate of COPD exacerbations per person‐year: For this outcome, we found one relevant study with 12 months of follow‐up (n = 36). Results showed no significant differences between vaccine and control groups (RR 0.87, 95% CI 0.44 to 1.72). </p> <section id="CD001390-sec-0077"> <h6 class="title">Lung function</h6> <p><a href="./references#CD001390-fig-0020" title="">Analysis 1.13</a>: FEV<sub>1</sub>: We found one relevant study with follow‐up of 24 months (n = 144). Results showed no significant differences between vaccine and control groups for measurements taken at three, 12 and 24 months. </p> </section> <section id="CD001390-sec-0078"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD001390-fig-0021" title="">Analysis 1.14</a>: St George's Respiratory Questionnaire (SGRQ) overall score: We found one relevant study with follow‐up of 24 months (n = 144). Results showed no significant differences between vaccine and control groups for measurements taken at three, 12 and 24 months. </p> </section> <section id="CD001390-sec-0079"> <h6 class="title">Adverse effects</h6> <p>No data were available for meta‐analysis. Adverse effects reported after vaccination in <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a> included erythema and induration observed in 22% and fever and headache in 5%. </p> <p><a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a> stated that "there were no adverse reactions to pneumococcal vaccine", and study authors for <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a> indicated that "no patient reported any local or systemic reaction to the vaccine". </p> </section> <section id="CD001390-sec-0080"> <h6 class="title">Sensitivity analysis</h6> <p>In sensitivity analysis of the likelihood of community‐acquired pneumonia with removal of studies available only as conference abstracts, and with <a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a> and <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a> excluded, effect size was lessened and became non‐significant and heterogeneity was eliminated, although the direction of effect remained the same (OR 0.80, 95% CI 0.51 to 1.25; four studies, n = 803). </p> </section> </section> </section> <section id="CD001390-sec-0081"> <h4 class="title">Comparison 2: 23‐valent pneumococcal polysaccharide vaccine (PPV‐23) versus 7‐valent diphtheria‐conjugated pneumococcal polysaccharide vaccine (PCV‐7); (one study; N = 181) </h4> <p>Only one study (n = 181) compared 23‐valent pneumococcal polysaccharide vaccine (PPSV‐23) with 7‐valent diptheria‐conjugated pneumococcal polysaccharide vaccine (PCV‐7) (<a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>). The follow‐up period was 48 months. This study found no statistically significant differences in likelihood between the two vaccines in terms of: </p> <p> <ol id="CD001390-list-0008"> <li> <p><a href="./references#CD001390-fig-0022" title="">Analysis 2.1</a>: incidence of community‐acquired pneumonia (OR 1.01, 95% CI 0.40 to 2.56); </p> </li> <li> <p><a href="./references#CD001390-fig-0023" title="">Analysis 2.2</a>: all‐cause mortality (OR 1.83, 95% CI 0.5 to 6.50); </p> </li> <li> <p><a href="./references#CD001390-fig-0024" title="">Analysis 2.3</a>: hospital admission (OR 0.91, 95% CI 0.47 to 1.74); and </p> </li> <li> <p><a href="./references#CD001390-fig-0025" title="">Analysis 2.4</a>: COPD exacerbation (OR 1.07, 95% CI 0.60 to 1.91). </p> </li> </ol> </p> <p>We assessed short‐term adverse effects of vaccines by using a seven‐day diary (<a href="./references#CD001390-fig-0026" title="">Analysis 2.5</a>) and noted a statistically significant difference for PPSV‐23 compared with PCV‐7 in the likelihood of fatigue (OR 2.40, 95% CI 1.15 to 5.00) and redness or discolouration ≤ 15 cm (OR 3.52, 95% CI 1.51 to 8.21). </p> <p>We found no statistically significant differences for PPSV‐23 compared with PCV‐7 in the likelihood of headache (OR 1.59, 95% CI 0.61 to 4.18), fever (OR 0.66, 95% CI 0.14 to 3.10), pain (OR 1.36, 95% CI 0.66 to 2.82), localised swelling (OR 1.61, 95% CI 0.74 to 3.52), limitation in arm movement (OR 1.85, 95% CI 0.88 to 3.90) or redness or discolouration &gt; 15 cm (OR 4.67, 95% CI 0.22 to 99.46). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001390-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001390-sec-0082"></div> <section id="CD001390-sec-0083"> <h3 class="title" id="CD001390-sec-0083">Summary of main results</h3> <p>For this systematic review update, a total of 12 randomised controlled trials (RCTs) (2171 participants) met our inclusion criteria. These investigators reported the effects of injectable pneumococcal polysaccharide vaccines (PPVs) in 2171 participants with chronic obstructive pulmonary disease (COPD). When compared with control for the primary outcome ‐ protection against community‐acquired pneumonia (CAP) ‐ results showed a lower likelihood with vaccine (odds ratio (OR) 0.59, 95% confidence interval (CI) 0.41 to 0.85; GRADE: moderate). The number needed to treat for an additional beneficial outcome (NNTB) to prevent one episode of CAP was 19 (95% CI 13 to 52). However, for pneumococcal pneumonia, researchers reported no significant difference with vaccination (Peto OR 0.26, 95% CI 0.05 to 1.31; GRADE: low), with only three studies (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>) measuring events and observing very few events. The difference in results between CAP and pneumococcal pneumonia may be related to both the paucity of events and non‐detection of pneumococcus. </p> <p>We found no difference in mortality from cardiorespiratory causes between vaccine and control (OR 1.07, 95% CI 0.69 to 1.66; GRADE: moderate) in three studies (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>), nor in all‐cause mortality in five studies (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a>; <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>) (OR 1.00, 95% CI 0.72 to 1.40; GRADE: moderate). </p> <p>The likelihood of hospital admission for any cause or for cardiorespiratory causes did not differ between vaccine and control groups; three studies reported admission for all causes (<a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>) (OR 0.74, 95% CI 0.32 to 1.74; GRADE: moderate), and one study for cardiorespiratory‐related causes (<a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>) (risk ratio (RR) 0.89, 95% CI 0.51 to 1.58; GRADE: moderate). The likelihood of an emergency department visit for any cause was lower in one study (<a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>) for vaccine than for control (OR 0.26, 95% CI 0.07 to 0.91; GRADE: moderate). </p> <p>The likelihood of a COPD exacerbation (<a href="#CD001390-fig-0007">Figure 7</a>) was significantly reduced (OR 0.60, 95% CI 0.39 to 0.93; GRADE: moderate) in four studies (<a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a>; <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>; <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>). The NNTB to prevent one episode of acute exacerbation was 8 (95% CI 5 to 58), which represents a reduction in risk from 608/1000 for control to 482/1000 for vaccination (<a href="./full#CD001390-fig-0001">Figure 1</a>). Three of these studies defined exacerbations of COPD as worsening respiratory symptoms beyond normal day‐to‐day variation, and the basis for exacerbations was not given in <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>, as the definition was not based on any need for additional treatment, and we were not able to classify the severity of the exacerbations. <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a> provided no definition of an exacerbation (published abstract only) and reported a lower exacerbation rate over six months (<a href="./references#CD001390-fig-0018" title="">Analysis 1.11</a>; mean difference (MD) ‐0.59, 95% CI ‐0.80 to ‐0.38). The rate of exacerbation in <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a> was not lower with vaccination; this study assessed the effect of vaccination on moderate exacerbations of COPD (<a href="./references#CD001390-bbs2-0116" title="BurgeS , WedzichaJA . COPD exacerbations: definitions and classifications. European Respiratory Journal2003;21:46s‐53s. ">Burge 2003</a>), defined as the requirement for treatment with parenteral corticosteroids with or without an antibiotic (<a href="./references#CD001390-fig-0019" title="">Analysis 1.12</a>; RR 0.87, 95% CI 0.44 to 1.72). </p> <p>One study (<a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>) reported local adverse effects in the vaccination group only, with erythema occurring in 22% of vaccinated participants. Another study (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>) found no significant difference in lung function between vaccine and control groups. </p> <p>No studies provided data on days of disability from respiratory illness or cost‐effectiveness of pneumococcal vaccination for meta‐analyses comparing vaccine and control. </p> <p>A single study (<a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a>) comparing 23‐valent pneumococcal polysaccharide vaccine and 7‐valent pneumococcal conjugate vaccine reported no differences in vaccination outcomes for CAP (OR 1.01, 95% CI 0.40 to 2.56), for mortality from all causes (OR 1.83, 95% CI 0.5 to 6.50), for hospital admission for any cause (OR 0.91, 95% CI 0.47 to 1.74) or for likelihood of experiencing a COPD exacerbation (OR 1.05, 95% CI 0.58 to 1.88). The likelihood of some mild adverse effects was higher with vaccination, with increased likelihood for PPV‐23 compared with PCV‐7 for fatigue (OR 2.40, 95% CI 1.15 to 5.00), local redness or discolouration ≤ 15 cm (OR 3.52, 95% CI 1.51 to 8.21) and limitation of arm movement (OR 1.85, 95% CI 0.88 to 3.90). </p> </section> <section id="CD001390-sec-0084"> <h3 class="title" id="CD001390-sec-0084">Overall completeness and applicability of evidence</h3> <p>Some studies described gender imbalance among participants; three studies included more than 80% male participants (<a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a>; <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a>). Cigarette smoking is recognised as the single biggest risk factor in the development of COPD, and in some studies, gender imbalance reflects the imbalance among smokers or among participants treated in veterans' healthcare facilities. We examined studies for differences in baseline characteristics that might potentially confound results. Baseline forced expiratory volume in one second (FEV<sub>1</sub>) and FEV<sub>1</sub>/forced vital capacity (FVC) did not significantly differ across groups in all fully published studies nor in studies for which study authors supplied data. Influenza vaccination was similar in <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> (100% vaccination and control) and <a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a> (62% vaccination, 52% control) ‐ two studies that contributed to analysis of COPD exacerbations, but <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a> and <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a> did not report influenza vaccine status. </p> <p>Treatments given in control groups varied. In <a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> and <a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a>, intervention groups received both a pneumococcal polysaccharide vaccine and an influenza vaccine, and the control group received only the influenza vaccine. In <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a>, <a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a>, <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a>,<a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a>, <a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a> and <a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a>, control groups did not receive a vaccine. Analysis by severity of COPD showed no significantly different effects for risk of pneumonia for severe compared with moderate airflow limitation. </p> <p>Results may be compared with those reported by RCTs that did not provide separate data for participants with COPD. In several older studies, for example, <a href="./references#CD001390-bbs2-0062" title="KlasterskyJ , MommenP , CantraineF , SafaryA . Placebo controlled pneumococcal immunisation in patients with bronchogenic carcinoma. European Journal of Cancer and Clinical Oncology1986;22:807‐13. ">Klastersky 1986</a>, in which participants had bronchogenic carcinoma, investigators found a small advantage for vaccination regarding likelihood of pneumococcal infection, <a href="./references#CD001390-bbs2-0042" title="GaillatJ , ZmirouD , MallaretMR , RouhanD , StahlJP , DelormasP , et al. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions [Essai clinique du vaccin antipneumococcique chez des personnes agées vivant en institution]. Revue d'Epidemiologie et de Sante Publique1985;33(6):437‐44. ">Gaillat 1985</a> found a lower likelihood of pneumonia but no effect on mortality among residents living in aged‐care facilities and <a href="./references#CD001390-bbs2-0064" title="KoivulaI , StenM , LeinonenM , MakelaPH . Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single‐blind population‐based trial. American Journal of Medine1997;103:281‐90. ">Koivula 1997</a> found no reduction in pneumonia events overall but a protective effect of pneumococcal vaccination in persons at increased risk of pneumonia (age ≥ 70 years, heart disease, lung disease, bronchial asthma, alcoholism, institutionalised or permanently bedridden). <a href="./references#CD001390-bbs2-0095" title="SimberkoffMS , CrossAP , Al‐IbrahimM , BaltchAL , GeiselerPJ , NadlerJ , et al. Efficacy of pneumococcal vaccine in high risk‐patients. Results of a Veterans Administration cooperative study. New England Journal of Medicine1986;315(21):1318‐27. ">Simberkoff 1986</a> showed no difference in pneumonia among high‐risk participants (age &gt; 55, chronic renal, hepatic, cardiac or pulmonary disease; alcoholism; or diabetes mellitus). <a href="./references#CD001390-bbs2-0080" title="OrtqvistA , HedlundJ , BurmanLA , ElbelE , HoferM , LeinonenM , et al. Randomised trial of 23‐valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle‐aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet1998;351(9100):399‐403. ">Ortqvist 1998</a>, which included 21% of participants 50 to 85 years of age with COPD, found no reduction in risk of pneumonia, pneumococcal pneumonia or mortality with vaccination compared with placebo. </p> <p>A recent large study (<a href="./references#CD001390-bbs2-0114" title="BontenMJM , HuijtsSM , BolkenbaasM , WebberC , PattersonS , GaultS , et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New England Journal of Medicine2015;372:1114‐25. ">Bonten 2015</a>) compared 13‐valent pneumococcal conjugate vaccine versus placebo in 84,496 participants over 65 years of age at 101 community‐based sites in the Netherlands, where pneumococcal vaccination in older adults was not routine. Risk of CAP in the PCV‐13 group compared with the placebo group was reduced by 37.7% (95% CI 14.3 to 55.1), and risk of invasive pneumococcal disease was reduced by 75.8% (95% CI 46.5 to 90.3) in modified intention‐to‐treat (ITT) analyses. Results are not available for participants with COPD, but overall, 12.3% of participants were current smokers, 4.9% reported a diagnosis of asthma and 25.4% had been given a diagnosis of heart disease. </p> <p>A systematic review (<a href="./references#CD001390-bbs2-0132" title="KewKM , SeniukovichA . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014;3:CD010115.pub2. ">Kew 2014</a>) showed that people with COPD treated with inhaled corticosteroids (budesonide and fluticasone, delivered alone or in combination with a long‐acting beta agonist (LABA)) had increased risk of serious pneumonia resulting in hospitalisation. In this current review of effects of pneumococcal vaccines for preventing pneumonia, only three studies reported the proportion of participants using corticosteroids; <a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a> indicated that 100% of participants were taking inhaled corticosteroids, <a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a> revealed that 24% used oral corticosteroids in the comparison with control and <a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a> described use of inhaled corticosteroids by 65% of participants in comparisons of PPV‐23 versus PCV‐7. Subgroup analyses were not possible. </p> <p>Clinical guidelines provided by internationally recognised respiratory societies have advocated use of pneumococcal vaccination in patients with COPD. Guidelines from the UK National Institute of Clinical Excellence (NICE) state that "pneumococcal vaccination and an annual influenza vaccination should be offered to all patients with COPD as recommended by the Chief Medical Officer" (<a href="./references#CD001390-bbs2-0140" title="National Institute of Clinical Excellence. COPD: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax2004;59(Suppl 1):181‐272. ">NICE 2004</a>). COPDX guidelines for Australia and New Zealand state that "pneumococcal immunisation (polyvalent covering 23 virulent serotypes) is recommended in people with COPD", and evidence for this recommendation is graded at level II (<a href="./references#CD001390-bbs2-0121" title="COPD Guidelines Steering Committee. The COPD‐X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease, March 2016. http://www.copdx.org.au/ (accessed 2 July 2016). ">COPDX 2016</a>). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines published jointly by the National Heart Lung and Blood Institute in the USA and the World Health Organization (WHO) advise that "pneumococcal vaccination should be offered to every COPD patient; vaccine appears to be more effective in older patients and those with more severe disease or cardiac comorbidity" (<a href="./references#CD001390-bbs2-0127" title="GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.com (accessed 2 July 2016). ">GOLD 2016</a>). </p> <p>The WHO (<a href="./references#CD001390-bbs2-0157" title="World Health Organization. WHO position paper on pneumococcal vaccines 2012. http://www.who.int/immunization/position_papers/PP_pneumococcal_April_2012_summary.pdf (accessed 8 April 2014). ">WHO 2012</a>) has made recommendations for use of pneumococcal vaccines in children, which are influencing pneumococcal disease, carriage and herd protection. Pneumococcal conjugated vaccines PCV‐10 and PCV‐13 are licensed for prevention of invasive disease, pneumonia and acute otitis media caused by respective vaccine serotypes in children from six weeks to five years of age, with high vaccine efficacy. The WHO recommends that inclusion of PCVs be given priority in childhood immunisation programmes worldwide, especially in countries with under‐five‐mortality of &gt; 50/1000 live births. Although herd effects of immunisation in children have reduced invasive pneumococcal disease (IPD), it is recommended that adults over 65 should be immunised. </p> <p>The studies included in this review reported a low frequency of proven pneumococcal pneumonia; thus we acknowledge the possibility of a type 2 error, given the rare events reported. Investigators have found that the overall contribution of pneumococcal pneumonia to overall CAP varies (<a href="./references#CD001390-bbs2-0147" title="RodrigoC , BewickT , SheppardC , GreenwoodS , McKeeverTM , TrotterCL , et al. Impact of infant 13‐valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. European Respiratory Journal2015;45(6):1632‐41. ">Rodrigo 2015</a>); between 2008 and 2013, rates of 17.1% to 37.3% were reported. </p> <p>A recent systematic review aimed to determine the incidence and burden of vaccine‐preventable pneumococcal disease in the adult population in the UK (<a href="./references#CD001390-bbs2-0118" title="ChalmersJD , CamplingJ , DickerA , WoodheadM , MadhavaH . A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulmonary Medicine2016;16:77. ">Chalmers 2016</a>). This study found a high burden of pneumococcal disease among adults, along with substantial ongoing changes in the epidemiology of pneumococcal disease. Among those &gt; 65 years of age, the incidence of IPD in 2013‐2014 was 20.58 per 100,000 population. However, the incidence of PCV13 serotype IPD among people &gt; 65 years of age was 10.33 per 100,000 population from 2008 to 2010, and fell to 3.72 per 100,000 in 2013‐2014. In this population, PCV‐7 serotypes were reduced from 4.58 per 100,000 in 2008 to 2010 to 0.53 per 100,000 population in 2013‐2014. </p> </section> <section id="CD001390-sec-0085"> <h3 class="title" id="CD001390-sec-0085">Quality of the evidence</h3> <p>We graded evidence showing beneficial effects on CAP (OR 0.62, 95% 0.43 to 0.89) and effects on mortality estimates (OR 1.07, 95% CI 0.69 to 1.66 for cardiorespiratory causes; OR 1.00, 95% CI 0.72 to 1.40 for all‐cause mortality) as having moderate quality. We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different. We graded evidence for the unchanged likelihood of hospital admission for any cause (OR 0.74, 95% CI 0.32 to 1.74) as having moderate quality. We graded the quality of evidence for the lower likelihood of an acute exacerbation of COPD (OR 0.25, 95% CI 0.16 to 0.38) as moderate; lack of participant and/or personnel blinding may have led to better general care and treatment for patients with COPD in the vaccinated group. </p> </section> <section id="CD001390-sec-0086"> <h3 class="title" id="CD001390-sec-0086">Potential biases in the review process</h3> <section id="CD001390-sec-0087"> <h4 class="title">Methodological limitations</h4> <p>Twelve studies involving 2171 participants contributed data to this review. At the review level, we believe incomplete identification of studies was not an issue, and we found no evidence of publication bias. The average number of participants per study was 187, although individual studies reported from 36 to 600 participants; these relatively low numbers are probably too small, given the incidence of pneumococcal infection among study populations. It is likely that larger studies with participant numbers of around 1000 would be needed to demonstrate statistically significant effects. </p> </section> </section> <section id="CD001390-sec-0088"> <h3 class="title" id="CD001390-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review current to June 2012 (<a href="./references#CD001390-bbs2-0136" title="MoberleyS , HoldenJ , TathamDP , AndrewsRM . Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD000422.pub3] ">Moberley 2013</a>) assessed the efficacy and effectiveness of PPVs in preventing pneumococcal disease or death among adults. In 18 RCTs involving 64,852 participants, investigators provided strong evidence of PPV efficacy against IPD (OR 0.26, 95% CI 0.14 to 0.45). They found efficacy against all‐cause pneumonia in low‐income (OR 0.54, 95% CI 0.43 to 0.67) but not in high‐income countries among the general population (OR 0.71, 95% CI 0.45 to 1.12) and among adults with chronic illness (OR 0.93, 95% CI 0.73 to 1.19). Study authors noted that vaccine efficacy against primary outcomes appeared poorer among adults with chronic illness, but small number of identified studies limited power to detect significant effects. This review also found no significant change in all‐cause mortality (OR 0.90, 95% CI 0.74 to 1.09). </p> <p>Review authors have assessed evidence for effectiveness of pneumococcal vaccine in other chronic respiratory conditions; a systematic review of children and adults with bronchiectasis, current to November 2008, identified no eligible RCTs (<a href="./references#CD001390-bbs2-0119" title="ChangCC , SingletonRJ , MorrisPS , ChangAB . Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006316.pub3] ">Chang 2009</a>). A systematic review, current to May 2014, conducted to assess the efficacy of pneumococcal vaccines in reducing morbidity among people with cystic fibrosis, also identified no relevant trials (<a href="./references#CD001390-bbs2-0117" title="BurgessL , SouthernKW . Pneumococcal vaccines for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD008865.pub3] ">Burgess 2014</a>). A systematic review of the efficacy of pneumococcal vaccine in reducing mortality or morbidity from pneumococcal disease among patients with asthma (<a href="./references#CD001390-bbs2-0152" title="SheikhA , AlvesB , DhamiS . Pneumococcal vaccine for asthma. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD002165] ">Sheikh 2002</a>) found no evidence of effects on acute asthma exacerbations. </p> <p>Studies using a retrospective, case‐control design that often included people with chronic lung conditions showed the efficacy of pneumococcal vaccination to be approximately 50% to 80% against invasive pneumococcal disease in high‐risk populations (<a href="./references#CD001390-bbs2-0033" title="FedsonDS , ShapiroED , LaForceFM , MufsonMA , MusherDM , SpikaJS , et al. Pneumococcal vaccine after 15 years of use. Another view. Archives of Internal Medicine1994;154(22):2531‐5. ">Fedson 1994</a>; <a href="./references#CD001390-bbs2-0071" title="LeophonteP , NeukirchF . Anti‐pneumococci vaccination: role and indications in the prevention of community acquired infections of the lower respiratory tract. Medecine et Maladies Infectieuses2001;31(4):181‐94. ">Leophonte 2001</a>). Prospective cohort studies have generally failed to show reductions in the risk of non‐bacteraemic infection, although <a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a> and <a href="./references#CD001390-bbs2-0056" title="JacksonL , NeuzilK , YuO , BensonP , BarlowW , AdamsA , et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. New England Journal of Medicine2003;348(18):1747‐55. ">Jackson 2003</a> demonstrated protection against bacteraemia. Regardless of design, most studies have found that the protective efficacy of vaccination is uniformly diminished in elderly and immunocompromised individuals. Although cohort studies are potentially easier to conduct logistically (<a href="./references#CD001390-bbs2-0129" title="HakE , HoesAW , NordinJIM , NicholKL . Benefits of influenza vaccine in US elderly ‐ appreciating issues of confounding bias and precision. International Journal of Epidemiology2006;35(3):800‐2. ">Hak 2006</a>), evidence from these studies is subject to limitations in generalisability (<a href="./references#CD001390-bbs2-0129" title="HakE , HoesAW , NordinJIM , NicholKL . Benefits of influenza vaccine in US elderly ‐ appreciating issues of confounding bias and precision. International Journal of Epidemiology2006;35(3):800‐2. ">Hak 2006</a>) and in interpretation (<a href="./references#CD001390-bbs2-0131" title="JacksonLA , JacksonML , NelsonJC , NeuzilKM , WeissNS . Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology2006;35(2):337‐44. ">Jackson 2006</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001390-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="In the control group, 608 out of 1000 people had one or more exacerbations over 6 to 24 months, compared with 482 (95% CI 377 to 591) out of 1000 for the active treatment group." data-id="CD001390-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>In the control group, 608 out of 1000 people had one or more exacerbations over 6 to 24 months, compared with 482 (95% CI 377 to 591) out of 1000 for the active treatment group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001390-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD001390-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD001390-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 Community‐acquired pneumonia: at least 1 episode." data-id="CD001390-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 Community‐acquired pneumonia: at least 1 episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.4 Death from cardiorespiratory causes." data-id="CD001390-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.4 Death from cardiorespiratory causes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 At least 1 COPD exacerbation." data-id="CD001390-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 At least 1 COPD exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 1 Community‐acquired pneumonia: at least 1 episode." data-id="CD001390-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 1 Community‐acquired pneumonia: at least 1 episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 2 Community‐acquired pneumonia: rate per person‐year." data-id="CD001390-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 2 Community‐acquired pneumonia: rate per person‐year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 3 Pneumococcal pneumonia: at least 1 episode." data-id="CD001390-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 3 Pneumococcal pneumonia: at least 1 episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 4 Death from cardiorespiratory causes." data-id="CD001390-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 4 Death from cardiorespiratory causes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 5 Death from all causes." data-id="CD001390-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 5 Death from all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 6 Hospital admission, any cause: at least 1 episode." data-id="CD001390-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 6 Hospital admission, any cause: at least 1 episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 7 Hospital admission: cardiorespiratory‐related." data-id="CD001390-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 7 Hospital admission: cardiorespiratory‐related.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 8 Hospital admission: all‐cause." data-id="CD001390-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 8 Hospital admission: all‐cause.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 9 ED visit, any cause: at least 1 episode." data-id="CD001390-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 9 ED visit, any cause: at least 1 episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 10 At least 1 COPD exacerbation." data-id="CD001390-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 10 At least 1 COPD exacerbation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 11 COPD exacerbation rate." data-id="CD001390-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 11 COPD exacerbation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 12 COPD exacerbations: rate/person‐year." data-id="CD001390-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 12 COPD exacerbations: rate/person‐year.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 13 Lung function: FEV1 (L)." data-id="CD001390-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 13 Lung function: FEV<sub>1</sub> (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pneumococcal vaccine versus control, Outcome 14 Quality of life: SGRQ overall." data-id="CD001390-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Pneumococcal vaccine versus control, Outcome 14 Quality of life: SGRQ overall. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 1 Community‐acquired pneumonia: at least 1 episode." data-id="CD001390-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 1 Community‐acquired pneumonia: at least 1 episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 2 Death from all causes." data-id="CD001390-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 2 Death from all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 3 Hospital admission, any cause: at least 1 episode." data-id="CD001390-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 3 Hospital admission, any cause: at least 1 episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 4 Acute exacerbation COPD." data-id="CD001390-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 4 Acute exacerbation COPD.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 5 Adverse effects." data-id="CD001390-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Comparison PPV‐23 versus PCV‐7, Outcome 5 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis by follow‐up period/subgroup, Outcome 1 Pneumonia by lung function at baseline." data-id="CD001390-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Analysis by follow‐up period/subgroup, Outcome 1 Pneumonia by lung function at baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis by follow‐up period/subgroup, Outcome 2 Hospital admission, any cause: by follow‐up periods." data-id="CD001390-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Analysis by follow‐up period/subgroup, Outcome 2 Hospital admission, any cause: by follow‐up periods. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis by follow‐up period/subgroup, Outcome 3 Hospital admission, cardiorespiratory‐related: by follow‐up periods." data-id="CD001390-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Analysis by follow‐up period/subgroup, Outcome 3 Hospital admission, cardiorespiratory‐related: by follow‐up periods. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis by follow‐up period/subgroup, Outcome 4 Emergency department visit, any cause: by follow‐up period." data-id="CD001390-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Analysis by follow‐up period/subgroup, Outcome 4 Emergency department visit, any cause: by follow‐up period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis by follow‐up period/subgroup, Outcome 5 Emergency visits (by cause)." data-id="CD001390-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Analysis by follow‐up period/subgroup, Outcome 5 Emergency visits (by cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001390-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/urn:x-wiley:14651858:media:CD001390:CD001390-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_t/tCD001390-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis by follow‐up period/subgroup, Outcome 6 At least 1 COPD exacerbation: varying follow‐up." data-id="CD001390-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Analysis by follow‐up period/subgroup, Outcome 6 At least 1 COPD exacerbation: varying follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/media/CDSR/CD001390/image_n/nCD001390-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001390-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pneumoccocal vaccination to prevent pneumonia in chronic obstructive pulmonary disease?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease? </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> pneumococcal vaccine<br/> <b>Comparison:</b> control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pneumococcal vaccine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia, community acquired, at least 1 episode<br/> Follow‐up: range 6 to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (67 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.59 (0.41 to 0.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1372<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitations with lack of participant blinding and no use of placebo in 3 studies. NNTB to prevent 1 episode of CAP = 19 (95% CI 13 to 52) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumococcal pneumonia, at least 1 episode<br/> Follow‐up: range 6 to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.26<br/> (0.05 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1158<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very few confirmed episodes of pneumococcal pneumonia. Rate of pneumococcal CAP to total CAP from 2008 to 2013 varied from 17.1% to 37.3% of cases (<a href="./references#CD001390-bbs2-0147" title="RodrigoC , BewickT , SheppardC , GreenwoodS , McKeeverTM , TrotterCL , et al. Impact of infant 13‐valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. European Respiratory Journal2015;45(6):1632‐41. ">Rodrigo 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from cardiorespiratory causes<br/> Follow‐up: range 24 to 48 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (70 to 153) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.07<br/> (0.69 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>888<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from all causes<br/> Follow‐up: range 12 to 48 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1000<br/> (125 to 217) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.72 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1053<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission: any cause, at least 1 episode<br/> Follow‐up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (29 to 140) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/> (0.32 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD exacerbation: at least 1 episode<br/> Follow‐up: range 6 to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>482 per 1000<br/> (377 to591) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.60 (0.39 to 0.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitations with lack of or unclear participant blinding in 3 studies. NNTB = 8 (95% CI 5 to 58); see <a href="./full#CD001390-fig-0001">Figure 1</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function: FEV<sub>1</sub> (L)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean lung function: FEV<sub>1</sub> (L) was 1.43 L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean lung function: FEV<sub>1</sub> (L) in the intervention group was 0.12 L lower (7.17 lower to 6.93 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference in lung function seen at 3 or 24 months in 1 study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; OR: odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Study limitations increase risk of performance and detection bias. </p> <p><sup>b</sup>substantial heterogeneity present. </p> <p><sup>c</sup>Wide confidence interval; few events in 2 studies, no events in 1 study. </p> <p><sup>d</sup>Wide confidence interval; effect size includes the null. </p> <p><sup>e</sup>Single study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pneumoccocal vaccination to prevent pneumonia in chronic obstructive pulmonary disease?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001390-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vaccine 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting/Follow‐up, months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age/% male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean FEV<sub>1</sub> (L) or % predicted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% AE 12 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% prior pneumonia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% current smokers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0001" title="AlfagemeI , ReyesN , VazquezR , PerezJ , Munoz , HernandezM , et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest2004;126(4 Suppl):837S. AlfagemeI , VazquezR , ReyesN , MunozJ , FernandezA , HernandezM , et al. Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD. Thorax2006;61:189‐95. ">Alfageme 2006</a> (n = 600) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seville, Spain/32 median</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 ± 0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0002" title="DavisAL , ArandaC , ChristiansonL , SchiffmanG . Effects of 14‐valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest1984;85(Suppl):82‐3. [DOI: 10.1378/chest.85.6_Supplement.82S‐a] DavisAL , ArandaCP , SchiffmanG , ChristiansonLC . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest1987;92(2):204‐12. ">Davis 1987</a> (n = 103) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14‐valent PPV 0.5 mL SC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline 0.5 mL SC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New York, USA/24 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63/NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 ± 0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0003" title="DransfieldMT , HarndenS , BurtonRL , AlbertRK , BaileyWC , CasaburiR , et al. Long‐term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases2012;55:e35‐44. DransfieldMT , NahmMH , HanMK , HarndenS , CrinerGJ , MartinezFJ , et al. Superior immune response to protein‐conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(6):499‐505. NCT00457977 . Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). ">Dransfield 2009</a> (n = 181) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐valent PCV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA 21 centres/48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64/37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0004" title="FurumotoA , OhkusaY , ChenM , KawakamiK , MasakiH , SueyasuY , et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine2008;26(33):4284‐9. ">Furumoto 2008</a> (n = 55 with COPD ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14‐valent PPV + influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kyushu &amp; Okinawa, Japan/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0005" title="KostinovMP , RyzhovAA , MagarshakOO , ZhirovaSN , ProtasovAD , ErofeevIuV , et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv2014;86(3):28‐33. ">Kostinov 2014</a> (Russian paper) (n = 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Russia/12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30‐70/36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0006" title="LeechJA , GervaisA , RubenFL . Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal1987;136(4):361‐5. ">Leech 1987</a> (n = 189) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14‐valent PPV + influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline + influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montreal Canada/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 ± 0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0007" title="NCT01381367 . PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). ">Lin 2013</a> (abstract &amp; poster) (n = 36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taipei, Taiwan/12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71/89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1% to 45%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (&gt; 1500 mcg/d)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0008" title="SteentoftJ , KonradsenHB , HilskovJ , GiglasonG , AndersenJR . Response to pneumococcal vaccine in chronic obstructive lung disease ‐ the effect of ongoing, systemic steroid treatment. Vaccine2006;24:1408‐12. ">Steentoft 2006</a> (n = 49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV 0.5 mL SC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65‐72/55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 to 1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OCS 24%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0009" title="TeramotoS , YamamotoH , YamaguchiY , HanaokaY , IshilM , OuchiY , et al. Clinical efficacy of anti‐pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A137. ">Teramoto 2007</a> (Abstract) (n = 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0010" title="TrofimovVI , ShaporovaNL , MarchenkoVN , SmirnovaIaA . [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii2010;4:41‐4. ">Trofimov 2010</a> (Russian paper) (n = 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Russia/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0011" title="Ya TseimakhI , MartynenkoI , ParaevaS . Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2006;28(Suppl 50):178s [P1091]. ">Ya Tseimakh 2006</a> (abstract) (n = 373) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Russia/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OCS not allowed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001390-bbs2-0012" title="YilmazD , UzaslanE , EgeE . Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2182. ">Yilmaz 2013</a> (abstract &amp; unpublished paper) (n = 144) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐valent PPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey &amp; UK/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65/93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 L ± 0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AE = acute exacerbation of COPD.</p> <p>ICS = inhaled corticosteroids.</p> <p>OCS = oral corticosteroids.</p> <p>PCV = diphtheria‐conjugated pneumococcal polysaccharide vaccine.</p> <p>PPV = pneumococcal polysaccharide vaccine.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/full#CD001390-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001390-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pneumococcal vaccine versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Community‐acquired pneumonia: at least 1 episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.41, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.42, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PPV‐14 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.10, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Community‐acquired pneumonia: rate per person‐year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.12, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pneumococcal pneumonia: at least 1 episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.05, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 PPV‐14 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [0.15, 393.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Death from cardiorespiratory causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.69, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.66, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PPV‐14 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.44, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Death from all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.69, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PPV‐14 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.48, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hospital admission, any cause: at least 1 episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.32, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.32, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hospital admission: cardiorespiratory‐related <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PPV‐14 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hospital admission: all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 ED visit, any cause: at least 1 episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 At least 1 COPD exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 COPD exacerbation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐0.80, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 COPD exacerbations: rate/person‐year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 PPV‐23 serotypes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.44, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Lung function: FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Quality of life: SGRQ overall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pneumococcal vaccine versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001390-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison PPV‐23 versus PCV‐7</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Community‐acquired pneumonia: at least 1 episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death from all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospital admission, any cause: at least 1 episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Acute exacerbation COPD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Redness or discolouration ≤ 15 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Redness or discolouration &gt; 15 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Localised swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Limitation of arm movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison PPV‐23 versus PCV‐7</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001390-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Analysis by follow‐up period/subgroup</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pneumonia by lung function at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 FEV1 &lt; 40% expected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.23, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 FEV1 ≥ 40% expected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospital admission, any cause: by follow‐up periods <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.23, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 6‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.23, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 12‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.11, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospital admission, cardiorespiratory‐related: by follow‐up periods <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 7‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 13‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.69, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 19‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.24, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Emergency department visit, any cause: by follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 3‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 12‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Emergency visits (by cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Due to URTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.68, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Due to LRTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.75, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Due to pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.52, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 At least 1 COPD exacerbation: varying follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.34, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.41, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 &gt; 12‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.15, 0.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Analysis by follow‐up period/subgroup</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001390.pub4/references#CD001390-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001390.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001390-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001390-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001390-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD001390-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001390-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001390-note-0003">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001390\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001390\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001390\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001390\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001390\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001390.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001390.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001390.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001390.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001390.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714389335"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001390.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714389339"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001390.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6d728c959377',t:'MTc0MDcxNDM4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 